Product Description

Vinorelbine is an antimitotic chemotherapeutic agent primarily used to treat various malignancies, including breast cancer and non-small cell lung cancer (NSCLC). Initially approved for NSCLC treatment in the 1990s, this semi-synthetic vinca alkaloid exhibits broad-spectrum antitumor activity with a more favorable toxicity profile. Its mechanism involves inhibiting tubulin polymerization, thereby disrupting microtubule assembly during mitosis. This results in metaphase arrest of cell division, demonstrating cell cycle-specific action.

Screeningbio‘s K562/Vinorelbine resistance cell line generated by exposing to increasing concentration of drug for certain period of time. After stable acquire resistance, cells were harvested and characterized for drug resistance by 7 days proliferation assay.

Data

Target Background

Vinorelbine (Navelbine) is a semi‑synthetic vinca alkaloid that inhibits microtubule polymerization by binding to tubulin, thereby preventing mitotic spindle formation and leading to cell cycle arrest (primarily in the G2/M phase) and apoptosis in rapidly dividing cancer cells. It is widely used in the treatment of non‑small cell lung cancer, advanced breast cancer, and ovarian carcinoma. However, the development of drug resistance remains a major challenge limiting its long‑term efficacy in these malignancies.

Mechanistically, vinorelbine resistance arises through multiple cellular adaptations. Alterations in β‑tubulin isotypes (e.g., increased βIII‑tubulin expression) or mutations in tubulin binding sites reduce drug binding affinity, while upregulation of efflux transporters such as P‑glycoprotein (MDR1/ABCB1) and MRP1 (ABCC1) decreases intracellular drug accumulation. Additionally, activation of survival pathways—including PI3K/Akt, MAPK/ERK, and NF‑κB signaling—promotes anti‑apoptotic responses. Changes in microtubule‑associated proteins (MAPs) such as tau and MAP4, as well as enhanced autophagy or epithelial–mesenchymal transition (EMT), also contribute to reduced drug sensitivity.

Understanding these mechanisms is critical for designing strategies to overcome resistance, such as combination therapy with efflux transporter inhibitors, targeting compensatory signaling networks (e.g., PI3K/Akt or NF‑κB inhibitors), modulating tubulin isotype expression, or employing patient‑derived resistant cell models to guide personalized therapy development.